These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 21653966)

  • 1. An analysis of how the GAVI alliance and low- and middle-income countries can share costs of new vaccines.
    Saxenian H; Cornejo S; Thorien K; Hecht R; Schwalbe N
    Health Aff (Millwood); 2011 Jun; 30(6):1122-33. PubMed ID: 21653966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability?
    Lydon P; Levine R; Makinen M; Brenzel L; Mitchell V; Milstien JB; Kamara L; Landry S
    Vaccine; 2008 Dec; 26(51):6706-16. PubMed ID: 18952134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?
    Brenzel L
    Vaccine; 2015 May; 33 Suppl 1():A93-8. PubMed ID: 25919183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Projections of costs, financing, and additional resource requirements for low- and lower middle-income country immunization programs over the decade, 2011-2020.
    Gandhi G; Lydon P; Cornejo S; Brenzel L; Wrobel S; Chang H
    Vaccine; 2013 Apr; 31 Suppl 2():B137-48. PubMed ID: 23598475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs of vaccine programs across 94 low- and middle-income countries.
    Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
    Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gavi's Transition Policy: Moving From Development Assistance To Domestic Financing Of Immunization Programs.
    Kallenberg J; Mok W; Newman R; Nguyen A; Ryckman T; Saxenian H; Wilson P
    Health Aff (Millwood); 2016 Feb; 35(2):250-8. PubMed ID: 26858377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lessons learned in shaping vaccine markets in low-income countries: a review of the vaccine market segment supported by the GAVI Alliance.
    Gilchrist SA; Nanni A
    Health Policy Plan; 2013 Dec; 28(8):838-46. PubMed ID: 23174880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Financial challenges of immunization: a look at GAVI.
    Kaddar M; Lydon P; Levine R
    Bull World Health Organ; 2004 Sep; 82(9):697-702. PubMed ID: 15628208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustainability of National Immunization Programme (NIP) performance and financing following Global Alliance for Vaccines and Immunization (GAVI) support to the Democratic Republic of the Congo (DRC).
    Le Gargasson JB; Breugelmans JG; Mibulumukini B; Da Silva A; Colombini A
    Vaccine; 2013 Apr; 31(15):1886-91. PubMed ID: 23462529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Financing children's vaccines.
    Nelson EA; Sack D; Wolfson L; Walker DG; Seng LF; Steele D
    Vaccine; 2009 Nov; 27 Suppl 5():F12-7. PubMed ID: 19931710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Country Ownership And Gavi Transition: Comprehensive Approaches To Supporting New Vaccine Introduction.
    Shen AK; Weiss JM; Andrus JK; Pecenka C; Atherly D; Taylor K; McQuestion M
    Health Aff (Millwood); 2016 Feb; 35(2):272-6. PubMed ID: 26858380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustaining GAVI-supported vaccine introductions in resource-poor countries.
    Zuber PL; El-Ziq I; Kaddar M; Ottosen AE; Rosenbaum K; Shirey M; Kamara L; Duclos P
    Vaccine; 2011 Apr; 29(17):3149-54. PubMed ID: 21354249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for financial sustainability of immunization programs: a review of the strategies from 50 national immunization program financial sustainability plans.
    Kamara L; Milstien JB; Patyna M; Lydon P; Levin A; Brenzel L
    Vaccine; 2008 Dec; 26(51):6717-26. PubMed ID: 18955100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applying lessons learned from the USAID family planning graduation experience to the GAVI graduation process.
    Shen AK; Farrell MM; Vandenbroucke MF; Fox E; Pablos-Mendez A
    Health Policy Plan; 2015 Jul; 30(6):687-95. PubMed ID: 24974106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Country-level governance of global health initiatives: an evaluation of immunization coordination mechanisms in five countries of Asia.
    Grundy J
    Health Policy Plan; 2010 May; 25(3):186-96. PubMed ID: 19926659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Domestic funding opportunities for Tanzania as five new Middle-Income countries brace for reduced Gavi support for immunization.
    Thomas Mori A; Christopher Bulula N; Magodi R; Mwengee W
    Vaccine; 2022 May; 40(24):3278-3285. PubMed ID: 35527062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
    Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Public and private donor financing for health in developing countries.
    Howard LM
    Infect Dis Clin North Am; 1991 Jun; 5(2):221-34. PubMed ID: 1869807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the Global Alliance for Vaccines and Immunisation on diphtheria, tetanus, and pertussis vaccine coverage: an independent assessment.
    Lu C; Michaud CM; Gakidou E; Khan K; Murray CJ
    Lancet; 2006 Sep; 368(9541):1088-95. PubMed ID: 16997663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.